IconICLR
About: Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
Employees: 41,900
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
7% more funds holding in top 10
Funds holding in top 10: 15 [Q3] → 16 (+1) [Q4]
2.85% less ownership
Funds ownership: 94.92% [Q3] → 92.06% (-2.85%) [Q4]
11% less funds holding
Funds holding: 652 [Q3] → 580 (-72) [Q4]
26% less repeat investments, than reductions
Existing positions increased: 184 | Existing positions reduced: 248
29% less capital invested
Capital invested by funds: $22.4B [Q3] → $15.9B (-$6.43B) [Q4]
42% less first-time investments, than exits
New positions opened: 88 | Existing positions closed: 151
66% less call options, than puts
Call options by funds: $33.1M | Put options by funds: $96.4M
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
6 analyst ratings
Baird Eric Coldwell 47% 1-year accuracy 15 / 32 met price target | 10%upside $203 | Neutral Maintained | 4 Mar 2025 |
Barclays Luke Sergott 22% 1-year accuracy 11 / 51 met price target | 30%upside $240 | Overweight Maintained | 21 Feb 2025 |
Truist Securities Jailendra Singh 24% 1-year accuracy 8 / 33 met price target | 42%upside $262 | Buy Maintained | 13 Feb 2025 |
JP Morgan Casey Woodring 0% 1-year accuracy 0 / 6 met price target | 44%upside $265 | Overweight Maintained | 3 Feb 2025 |
RBC Capital Sean Dodge 41% 1-year accuracy 15 / 37 met price target | 42%upside $263 | Outperform Reiterated | 15 Jan 2025 |
Financial journalist opinion
Based on 385 articles about ICLR published over the past 30 days









